Sign up to access all valuation multiples
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
2007
3.6K+
LTM Revenue $353M
LTM EBITDA $126M
$3.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eris Lifesciences has a last 12-month revenue (LTM) of $353M and a last 12-month EBITDA of $126M.
In the most recent fiscal year, Eris Lifesciences achieved revenue of $330M and an EBITDA of $119M.
Eris Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eris Lifesciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $353M | XXX | $330M | XXX | XXX | XXX |
| Gross Profit | $267M | XXX | $246M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $126M | XXX | $119M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $90.0M | XXX | $80.6M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $50.7M | XXX | $40.3M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $255M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Eris Lifesciences's stock price is INR 1800 (or $21).
Eris Lifesciences has current market cap of INR 245B (or $2.8B), and EV of INR 268B (or $3.1B).
See Eris Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1B | $2.8B | XXX | XXX | XXX | XXX | $0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Eris Lifesciences has market cap of $2.8B and EV of $3.1B.
Eris Lifesciences's trades at 10.1x EV/Revenue multiple, and 28.2x EV/EBITDA.
Equity research analysts estimate Eris Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eris Lifesciences has a P/E ratio of 55.3x.
See valuation multiples for Eris Lifesciences and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | 10.1x | XXX | XXX | XXX |
| EV/EBITDA | 24.4x | XXX | 28.2x | XXX | XXX | XXX |
| EV/EBIT | 34.1x | XXX | 41.1x | XXX | XXX | XXX |
| EV/Gross Profit | 11.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 55.3x | XXX | 67.7x | XXX | XXX | XXX |
| EV/FCF | 77.6x | XXX | 34.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEris Lifesciences's last 12 month revenue growth is 16%
Eris Lifesciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $47K for the same period.
Eris Lifesciences's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eris Lifesciences's rule of X is 75% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eris Lifesciences and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 52% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $47K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eris Lifesciences acquired XXX companies to date.
Last acquisition by Eris Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Eris Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Eris Lifesciences founded? | Eris Lifesciences was founded in 2007. |
| Where is Eris Lifesciences headquartered? | Eris Lifesciences is headquartered in India. |
| How many employees does Eris Lifesciences have? | As of today, Eris Lifesciences has 3.6K+ employees. |
| Is Eris Lifesciences publicy listed? | Yes, Eris Lifesciences is a public company listed on BOM. |
| What is the stock symbol of Eris Lifesciences? | Eris Lifesciences trades under 540596 ticker. |
| When did Eris Lifesciences go public? | Eris Lifesciences went public in 2017. |
| Who are competitors of Eris Lifesciences? | Similar companies to Eris Lifesciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Eris Lifesciences? | Eris Lifesciences's current market cap is $2.8B |
| What is the current revenue of Eris Lifesciences? | Eris Lifesciences's last 12 months revenue is $353M. |
| What is the current revenue growth of Eris Lifesciences? | Eris Lifesciences revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Eris Lifesciences? | Current revenue multiple of Eris Lifesciences is 8.7x. |
| Is Eris Lifesciences profitable? | Yes, Eris Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eris Lifesciences? | Eris Lifesciences's last 12 months EBITDA is $126M. |
| What is Eris Lifesciences's EBITDA margin? | Eris Lifesciences's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Eris Lifesciences? | Current EBITDA multiple of Eris Lifesciences is 24.4x. |
| What is the current FCF of Eris Lifesciences? | Eris Lifesciences's last 12 months FCF is $39.5M. |
| What is Eris Lifesciences's FCF margin? | Eris Lifesciences's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Eris Lifesciences? | Current FCF multiple of Eris Lifesciences is 77.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
